Chipscreen's NDA for Novel Type 2 Diabetes Drug Accepted for China Review
publication date: Sep 20, 2019
Shenzhen Chipscreen Biosciences reported its new drug application for a first-in-class type 2 diabetes treatment was accepted for review in China. Chiglitazar, a novel small molecule peroxisome proliferator-activated receptor (PPAR) α/γ/δ pan-agonist, acts as an insulin sensitizer. The first PPAR pan-agonist to complete Phase III clinical trials, chiglitazar showed durable efficacy in glycemic control for patients with T2DM and metabolic syndrome. In August, Chipscreen completed a $147 million IPO on the Shanghai STAR board and rose 367% in its first trading day. More details....
Stock Symbol: (SHA: 688321)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.